EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes

Victor Sokolov iD, Tatiana Yakovleva iD, Leonid Stolbov iD, Robert C Penland iD, David Boulton, Joanna Parkinson, Weifeng Tang

CPT: Pharmacometrics & Systems Pharmacology · 2023

DOI: 10.1002/psp4.12956 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2023. Verfasst von Victor Sokolov und 6 weiteren Autor:innen. Beteiligte Einrichtung: M&S Decisions, Moscow, Russia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by abnormally high blood glucose concentrations due to dysfunction of the insulin‐producing beta‐cells in the pancreas. Dapagliflozin, an inhibitor of renal glucose reabsorption, has the potential to improve often suboptimal glycemic control in patients with T1DM through insulin‐independent mechanisms and to partially mitigate the adverse effects associated with long‐term insulin administration. In this work, we have adapted a systems pharmacology model of type 2 diabetes mellitus to describe the T1DM condition and characterize the effect of dapagliflozin on short‐ and long‐term glycemic markers under various treatment scenarios. The developed platform serves as a quantitative tool for the in silico evaluation of the insulin‐glucose‐dapagliflozin crosstalk, optimization of the treatment regimens, and it can be further expanded to include additional therapies or other aspects of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHumansHypoglycemic AgentsBlood GlucoseSodium-Glucose Transporter 2GlucoseInsulinBenzhydryl CompoundsGlucosides

Substanzen

Hypoglycemic AgentsBlood GlucoseSodium-Glucose Transporter 2 InhibitorsSodium-Glucose Transporter 2GlucoseInsulindapagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • M&S Decisions, Moscow, Russia.
  • STU "Sirius", Sochi, Russia.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Waltham, Massachusetts, USA.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Victor Sokolov, Tatiana Yakovleva, Leonid Stolbov, Robert C Penland

Zitieren

APA

Sokolov, V., Yakovleva, T., Stolbov, L., Penland, R. C., Boulton, D., Parkinson, J., & Tang, W. (2023). A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.12956

Vancouver

Sokolov V, Yakovleva T, Stolbov L, Penland RC, Boulton D, Parkinson J, et al. A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes. CPT: Pharmacometrics & Systems Pharmacology. 2023. doi:10.1002/psp4.12956

BibTeX
@article{Sokolov2023,
  author = {Sokolov, Victor and Yakovleva, Tatiana and Stolbov, Leonid and Penland, Robert C and Boulton, David and Parkinson, Joanna and Tang, Weifeng},
  title = {A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2023},
  doi = {10.1002/psp4.12956}
}
Kostenlos starten →